Equillium doses first patient in Australia in Phase 1 study of EQ504; topline data expected Q2'27

Equillium has dosed the first patient in Australia in its Phase 1 clinical study of EQ504, a drug candidate to treat serious inflammatory diseases. Topline Phase 1 data is anticipated in Q2'27, and the dosing triggers a milestone closing of $20M, with the company selling 14.95M shares at $0.57/share and 20M pre-funded warrants at $0.56 each.

Detected & updated continuously · Source: Nebula